Currently out of the existing stock ratings of Kostas Biliouris, 29 are a BUY (74.36%), 10 are a HOLD (25.64%).

Kostas Biliouris

Work Performance Price Targets & Ratings Chart

Analyst Kostas Biliouris, currently employed at BMO, carries an average stock price target met ratio of 26.13% that have a potential upside of 21.33% achieved within 103 days.

Kostas Biliouris’s has documented 81 price targets and ratings displayed on 12 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on NTLA, Intellia Therapeutics at 10-Jan-2025.

Wall Street Analyst Kostas Biliouris

Analyst best performing recommendations are on BEAM (BEAM THERAPEUTICS ).
The best stock recommendation documented was for BEAM (BEAM THERAPEUTICS ) at 7/18/2022. The price target of $61 was fulfilled within 1 day with a profit of $2.99 (5.15%) receiving and performance score of 51.54.

Average potential price target upside

BEAM Beam Therapeutics  CNTA Centessa Pharmaceuticals PLC ADR CRSP Crispr Therapeutics AG DTIL Precision BioSciences GRPH Graphite Bio LEGN Legend Biotech Corp NTLA Intellia Therapeutics VERV Verve Therapeutics BMRN Biomarin Pharmaceutical ALNY Alnylam Pharmaceuticals FDMT 4D Molecular Therapeutics  SRPT Sarepta Therapeutics

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$80

$53.66 (203.72%)

$80

3 days ago
(28-Feb-2025)

0/6 (0%)

$53.66 (203.72%)

Buy

$78

$51.66 (196.13%)

$78

4 days ago
(27-Feb-2025)

0/3 (0%)

$50.89 (187.72%)

Hold

$26

$-0.34 (-1.29%)

$24

5 days ago
(26-Feb-2025)

6/7 (85.71%)

$-1.89 (-6.78%)

72

Buy

$39

1 months 2 days ago
(29-Jan-2025)

1/10 (10%)

$12.38 (46.51%)

118

3 months 25 days ago
(06-Nov-2024)

0/2 (0%)

$32.61 (73.46%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Kostas Biliouris is most bullish on?

Potential upside of $39.14 has been obtained for NTLA (INTELLIA THERAPEUTICS)

Which stock is Kostas Biliouris is most reserved on?

Potential downside of -$0 has been obtained for DTIL (PRECISION BIOSCIENCES)

What Year was the first public recommendation made by Kostas Biliouris?

On 2022

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?